Remibrutinib has 6 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Digoxin, Mao Inhibitors. Patients taking Remibrutinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 3
- Moderate
- 3
Major (3)
- Remibrutinib + Cyp3a Inducers— Concomitant use decreases remibrutinib exposure and may decrease efficacy. Avoid concomitant use.
- Remibrutinib + Digoxin— Remibrutinib increases P-gp substrate exposure. Monitor frequently for adverse reactions with substrates where minimal c…
- Remibrutinib + Mao Inhibitors— Concomitant use increases remibrutinib exposure and risk of adverse reactions. Avoid concomitant use.
Moderate (3)
- Remibrutinib + Acetyl Salicylic Acid— Doses up to 100 mg daily were allowed in clinical studies. Consider risks and benefits of concomitant antithrombotic use…
- Remibrutinib + Clopidogrel— Doses up to 75 mg daily were allowed in clinical studies. Consider risks and benefits of concomitant antithrombotic use.
- Remibrutinib + Oral Anticoagulants— No data available on concomitant use. Consider risks and benefits; concomitant use was not allowed in clinical studies.